TITLE: Serum Markers Predict Brain Death Due to Trauma and Hypoxia Within 32 hours of Injury

AUTHORS:
Daniel Rafter, MD[1,4] – danjamesrafter@gmail.com
Brett Sterk[1] - brettsterk@gmail.com
Zhuliu Li[1,2] - lixx3617@umn.edu
Tory Schaaf PhD[1,4]- schaa033@umn.edu
Rui Kuang PhD[2] - kuang@umn.edu
Michael Koller[1] - kolle153@umn.edu
Uzma Samadani MD PhD[1,3,4] - uzma@samadani.com

Corresponding Author:
Uzma Samadani MD PhD[1,3,4], 1 Veterans Drive, Dept of Neurosurgery, Minneapolis, MN 55417
uzma@samadani.com 917-388-5740

[1] Department of Bioinformatics and Computational Biology, University of Minnesota; 100 Church St S.E., Minneapolis MN 55455

[2] Department of Computer Science and Engineering, University of Minnesota; 100 Church St S.E., Minneapolis MN 55455

[3] Division of Neurosurgery, Minneapolis VA, 1 Veterans Drive, Minneapolis, MN 55417

[4] Neurosurgery, Centracare, 1406 6th Ave N, St Cloud, MN 56303

 RUNNING TITLE: UCH-L1, GFAP, and S100B predict traumatic and hypoxic brain death, a case series.

Abstract word count: 238/375
Text word count: 3678/4000
Number of references: 37/45
Number of tables and/or figures: 6/8
Number of videos: 0/2

ABSTRACT: Objective: Brain death is a controversial construct because proving irreversible cessation of neurologic function is difficult, and ascertaining the timepoint at which irreversibility has occurred is not currently possible. The ability to predict which traumatic (TBI) and hypoxic brain injuries will progress to brain death is also limited. We investigated how accurately neurologic serum markers can predict brain death and differentiate its etiology. **Methods:** This prospective observational study enrolled brain injury subjects presenting to a trauma center within 32 hours of injury. Levels of glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and S100 Calcium-Binding Protein B (S100B) were compared. Clinically brain dead (BD) subjects were further subdivided into high velocity trauma with presumed diffuse axonal injury (DAI), cardiopulmonary/respiratory arrest (CA/RA), and found down (FD). **Results:** The prognostic value of various biomarker combinations in identifying subjects progressing to brain death was assessed using machine learning. Prediction accuracy for GFAP, UCH-L1, and S100B in combination to predict brain death from among all other cohorts yielded an area under the curve (AUC) of 0.98 versus all other brain injury subjects. This model was also able to distinguish CA/RA BD from combined non-trauma controls and DAI BD with an AUC of 0.99. **Conclusion:** Serum concentrations of GFAP, UCH-L1, and S100B measured within 32 hours of traumatic and hypoxic brain injury have utility in prognosticating brain death by mechanism of injury as either hypoxic (CA/RA) or traumatic/unknown (DAI and FD).

Keywords:
-        Glial fibrillary acidic protein (GFAP)
-        S100 Calcium-Binding Protein B (S100β)
-        Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
-        Traumatic brain injury (TBI)
-        Brain death

INTRODUCTION:

The clinical standard for the determination of death by neurologic criteria relies on history, physical examination, and radiographic findings.[1] The concept of brain death remains controversial however, because it is difficult to prove that cessation of neurologic function either in the whole brain or brainstem is irreversible, and the point at which irreversibility has occurred is not readily ascertainable. [1] Limited cellular neuronal function may be rescued under particular circumstances[2] and broader neurological recovery is possible in cases of hypothermia, hypermagnesemia or other conditions. Nineteen different xenobiotic agents have been implicated in causing a transient neurologic mimic of brain death.[3] Some survivors of coldwater drowning and avalanche suffocations with hypothermic arrest may experience neurologic recovery.[4] Recent advances in whole body temperature-controlled perfusion allowed for full neurological recovery after 10 minutes of prolonged asystole with hypothermia.[5] Rare cases of "recovery after neurologic death" may further obfuscate both clinician and layperson understanding of the reversibility of brain death.[6]

The mechanistic heterogeneity of severe brain injury[7] implies that some injuries may potentially be more reversible than others. As such, early and accurate classification is critical for prognostication and potential therapeutic implementation.

Two of the mechanistically dichotomous pathologies that may potentially advance to brain death are traumatic diffuse axonal injury (DAI) and atraumatic anoxic or hypoxic brain injury. DAI results from high velocity shearing forces at the gray-white matter interface, particularly in the corpus callosum and brainstem.[8] Anoxia results after as little as 20 seconds of circulatory arrest depletes neuronal oxygen stores resulting in loss of consciousness. Continued insufficient circulatory support for 10 minutes is generally lethal.[9] Radiographic signs of hypoxic injury are frequently undetectable in the acute setting, and sequelae of structural disruption including global edema and diffusion weighted changes may not be evident until days after the original insult making accurate prognostication difficult.[10] As such, there is a strong need for improved diagnostic and prognostic measures of brain death in DAI, anoxic brain injury, and brain injury of unknown origin in order to make informed clinical decisions about withdrawing life support, avoiding futile interventions, allocating resources and monitoring progression and therapeutic responses.[11]

Serum biomarkers offer potential to aid in objective measurement and prognostication of brain injury[11], and have been examined in various brain injury cohorts including brain death.[12] In particular, glial fibrillary acidic protein (GFAP), the predominant filament protein in the astrocytic skeleton has demonstrated potential as a marker of astrocytic injury [13, 14], and is markedly upregulated during astrogliosis, a process in which astrocytes increase in size and number in response to traumatic and anoxic injury.[15, 16] Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is a neuron-specific protein, known for its role in the addition and removal of

ubiquitin from proteins.[17] Much like GFAP, UCH-L1 is elevated in the serum following TBI and is predictive of TBI severity and presence of intracranial lesions on head CT.[18] S100B is a well-studied biomarker that functions in astrocytes as a major homeostatic calcium-binding protein and is released into the serum after brain injury.[19] One study investigated S100B in both severe TBI and cardiac arrest patients, finding that concentrations measured at 12 hours post-admission were comparable between TBI and cardiac arrest groups as well as predictive of unfavorable neurologic outcome.[20]

The aim of this study is to explore the potential role of serum biomarkers in predicting brain death in both non-traumatic and traumatic brain injuries. Our goal is to develop a brain injury stratification model based on three serum markers GFAP, UCH-L1, and S100B concentrations, taken within 32 hours of hospital admission. This model will distinguish between those who suffered brain death and those who suffered a TBI with positive head CT or non-traumatic brain injury. Evaluation of these three different brain injury biomarkers along with the current recommendations may be useful in classifying the pathophysiology of injury as due to cardiac/respiratory arrest (CA/RA), unknown etiology/found down (FD), or diffuse axonal injury (DAI).

METHODS:

Study Design

Hennepin Healthcare Institutional Review Board approval (HSR #15-4079) was obtained for prospective enrollment of patients who presented to the emergency department of a level-1 trauma center between May 2016 and April 2017. Subjects were consented if they were able to pass the Galveston Orientation and Amnesia Test (GOAT) and met criteria for providing informed consent. If they were not able to provide informed consent initially, a legally authorized representative was consented and the subject was reconsented once able. Only in situations where the subject expired in the hospital and family or a legally authorized representative could not be contacted was informed consent waived. Informed consent or waiver of consent was obtained prior to data inclusion.

Blood Collection and Processing

Serum (18 mL) and plasma (12 mL) samples were collected at the time of enrollment in serum-separating tubes (SST) and K2EDTA vacutainers, respectively. The first blood sample was collected at admission (0 hr), second drawn within 8 hours of the reported time of injury, and a third was drawn 12 - 32 hours post-injury. At each collection point, approximately 40 mL of blood was drawn and distributed evenly into SST and EDTA vacutainers. Both sample types were held at room temperature for between 30 minutes at 2 hours prior to centrifugation for 10 minutes at 2380 rpm. Processed samples were aliquoted and stored at -80°C prior to shipment on

dry ice to Abbott Laboratories (Abbott Park, IL) for assay analysis. Serum samples were analyzed for UCH-L1, GFAP, and S100B. Results were reported in picograms/milliliter (pg/mL) for all biomarkers.

Data Analysis

Analysis and plotting was performed using Microsoft Excel 2016 (v16.0) and MATLAB (R2018b). Subject characteristics including demographic information, loss of consciousness (LOC) duration, GCS score, percentage with clinical CT, Marshall score, length of hospital stay, and discharge location were described using descriptive statistics. Only samples with at least one valid UCH-L1, GFAP, or S100B biomarker result were included in the analysis. Cohort biomarker levels were compared to blood samples from healthy controls from a single blood draw. Biomarker levels below the detectable limit prior to transformation were assigned a value of zero, but included in the analysis. Biomarker levels above the detectable limit (50,000 pg/ml for GFAP and 20,000 pg/ml for UCH-L1) were included in analysis as equal to the upper limit.

Descriptive statistics including mean, median, standard deviation, and interquartile range (IQR) were calculated where appropriate. Differences in mean raw concentrations between CTL, CTp, CTn, NT and BD groups at all timepoints measured within 32 hours were assessed using the t-test. Concentrations were log-transformed to achieve normality prior to plotting and ROC analysis.

Machine Learning

Support Vector Machine (SVM)[21] is utilized for the classification of the patient samples in our prediction tasks. Among the supervised learning methods, SVM generalizes well on new test data, and the decision function of SVM is simply defined by a subset of training samples without requiring training with big data.

Support vector machine and kernels

Given a set of training data $\{(\mathbf{x}_i, y_i)\}_{i=1}^{N}$ with $\mathbf{x}_i$ be the i-th sample vector and $y_i \in \{+1, -1\}$ as its label, the SVM outputs the score $f(\mathbf{x}_{\text{new}})$ of a new sample $\mathbf{x}_{\text{new}}$ as

$$f(\mathbf{x}_{\text{new}}) = \sum_{i=1}^{N} \alpha_i y_i K(\mathbf{x}_i, \mathbf{x}_{\text{new}}) + b,$$

where $K(\mathbf{x}_i, \mathbf{x}_j)$ is the kernel function defined with a mapping of the original feature space into a transformed space for non-linear classification. We use the most popular non-linear kernel functions Gaussian kernel and Polynomial kernel defined as

Polynomial kernel with degree d: $K(\mathbf{x}_i, \mathbf{x}_j) = (1 + \mathbf{x}_i^T \mathbf{x}_j)^d$

Gaussian kernel: $K(\mathbf{x}_i, \mathbf{x}_j) = \exp(-\frac{||\mathbf{x}_i - \mathbf{x}_j||^2}{\sigma^2})$

The α_i for $i = 1, \ldots, N$ are obtained by solving the optimization problem

$$\underset{\alpha_1,\ldots,\alpha_N}{\text{maximize}} \sum_i \alpha_i - \frac{1}{2} \sum_{i,j=1}^{N} \alpha_i \alpha_j y_i y_j K(\mathbf{x}_i, \mathbf{x}_j)$$

$$\text{subject to} \sum_{i=1}^{N} \alpha_i y_i = 0, \text{ and } 0 \leq \alpha_i \leq \frac{1}{2N\lambda}, \ \forall i = 1, \ldots, N,$$

where λ is a hyper-parameter.

After obtaining all the α_is, the scalar b is obtained as:

$$b = -0.5 * (\max_{j:y_j=-1} \sum_{i=1}^{N} \alpha_i y_i K(\mathbf{x}_i, \mathbf{x}_j) + \min_{j:y_j=1} \sum_{i=1}^{N} \alpha_i y_i K(\mathbf{x}_i, \mathbf{x}_j)).$$

RESULTS:

779 brain injury subjects and healthy controls enrolled during the study period and 331 were determined to have at least one valid biomarker result within 32 hours of injury. Of these eligible subjects, 21 expired during their initial admission with a final diagnosis of brain death. One subject was excluded due to invalid results on all three of the biomarkers of interest, GFAP, UCH-L1, and S100b, and another who suffered a gunshot wound to the head was excluded on the basis of penetrating brain injury. The remaining 19 BD subjects (13 male, 6 female), had a mean (SD) age of 58.6 (17.6) with a range of 24-87. For comparative purposes, 51 isolated TBI subjects with at least one valid biomarker result within 32 hours of injury were identified and further categorized as CT-positive (CTp) and CT-negative (CT-n) cohorts using the Marshall Classification. 21 CTp subjects (15 male, 6 female) had a mean (SD) age of 56.2 (16.8) with a range of 31-85 and 30 CTn subjects (21 male, 9 female) had a mean (SD) age of 50.4 (25.5) with a range of 4-95. 15 non-trauma (NT) subjects that survived their initial admission (8 male, 7 female) had a mean (SD) age of 53.8 (15.4) with a range of 18-86. Additionally, 41 healthy control subjects (CTL) (11 male, 30 female) had a mean (SD) age of 37.1 (14.0) with a range of 16-65. Characteristics of all cohorts are displayed in Table 1.

The highest GCS scores were observed in the CTn group with 93% having a high GCS (13-15, N=28), while 95% (N=18) of the BD subjects had low GCS scores (8 or less) at the time of arrival to the emergency department. 62% (N=13) of CTp subjects had a high GCS (13-15) while NT had only 40% (N=6) with a high GCS and the majority (53%, N=8) had a low GCS. LOC duration showed a similar trend with 50% (N=15) of CTn subjects having no LOC, while only 33% (N=5) of NT subjects had no LOC. 29% (N=6) of CTp had an LOC duration of 0 - 30 minutes, while most (74%, N=14) BD patients experienced greater than 24 hours of LOC prior to

brain death diagnosis. Unknown LOC duration (unable to be obtained) remained a significant portion of all groups with 48% (N=10) of CTp and 53% (N=8) of NT patients having unknown LOC duration. A head CT was obtained for all brain injury patients except for one patient, who was in the BD cohort. Mean (range) Marshall Score for groups were 3.1 (1 - 6) for BD subjects, 1 (1-1) for CTn, 2.14 (2 - 4) for CTp, and 2.47 (1 - 6) for NT. For the BD subjects, the most prevalent mechanism of injury was found down (FD, 53%, N=10), followed by cardio-pulmonary arrest (CA/RA, 37%, N=7) and high velocity trauma/presumed DAI (11%, N=2).

Measures of central tendency (mean, median), dispersion (standard deviation (SD), interquartile range [25-75%] (IQR)) for the time differences from reported time of injury to blood sample collection for each of the four subject groups were comparable. The mean (SD | median | IQR) time of injury to blood draw was 720.5 minutes (543.4 | 562 | 270-1,227) for BD, 671.8 minutes (529.9 | 465 | 234-1,284) for CTp, 581.7 minutes (598.4 | 295 | 140.75-1,214.25) for CTn, and 723.6 minutes (624.76 | 430 | 200-1,348) for NT. Within the BD cohort, the mean (SD | median | IQR) time of injury to blood sample collection for each mechanism of injury was 863.1 minutes (547.6 | 821 | 312-1,373) for FD, 505.1 minutes (501.8 | 320 | 205-525) for CA/RA, and 911.2 minutes (507.1 | 1,053 | 930-1,172) for DAI.

A total of 203 valid UCH-L1 samples were analyzed, 40 were in the BD group, 46 in the CTp group, 49 in the CTn group, 27 in the NT group, and 41 in the CTL group. Mean (SD) time from injury to blood collection was similar for all groups with 731.6 minutes (545.6) for BD, 688.0 minutes (534.7) for CTp, 581.7 minutes (598.4) for CTn, and 723.6 minutes (624.8) for NT cohorts. BD subjects had a median UCH-L1 concentration of 2,082.5 pg/mL (IQR: 537.5-4,506.3 pg/mL) compared to 395.9 pg/mL (IQR: 196.4-872.9 pg/mL) for CTp, 218.3 pg/mL (IQR: 122-388.2 pg/mL) for CTn, 164.5 pg/mL (IQR: 84.8-408 pg/mL) for NT, and 73.7 pg/mL (IQR: 44.2-113.1 pg/mL) for CTL subjects (Figure 1). Mean concentrations of UCH-L1 in the BD group were significantly higher than all other comparison groups and controls (p < 0.001; t-test). Of the BD subjects, median (IQR) UCH-L1 concentrations were 775.6 pg/mL (411.95-2,082.5 pg/mL) for FD, 4,421.9 pg/mL (2,228.3-11,774.1 pg/mL) for CA/RA, and 2,830.4 pg/mL (1,245.8-3,304.1 pg/mL) for DAI.

203 valid GFAP samples were analyzed, 40 within the BD group, 46 within the CTp group, 49 within the CTn group, 27 within the NT group, and 41 within the CTL group. Mean (SD) time from injury to blood collection was similar for all groups with 731.6 minutes (545.6) for BD, 688.0 minutes (534.7) for CTp, 581.7 minutes (598.4) for CTn, and 723.6 minutes (624.8) for NT cohorts. BD subjects had a median GFAP concentration of 12,622.7 pg/mL (IQR: 185.7-34,339.1 pg/mL) compared to 1,230.6 pg/mL (IQR: 181.9-2,527.1 pg/mL) for CTp, 48.7 pg/mL (IQR: 25.1-118.2 pg/mL) for CTn, 77.7 pg/mL (IQR: 33.4-1,833.0 pg/mL) for NT, and 9.4 pg/mL (IQR: 5.8-13.3 pg/mL) for CTL subjects (Figure 1). Mean concentrations of GFAP in the BD group were significantly higher than all other comparison groups and controls (p < 0.001; t-test). In the BD cohort, median (IQR) concentrations of GFAP were 24,959.7 pg/mL (15,565.2-

42,394.5 pg/mL) for FD, 65.75 pg/mL (31.9-472 pg/mL) for CA/RA, and 33,018.7 pg/mL (13,284.3-48,064.2 pg/mL) for DAI.

137 valid S100B samples were analyzed, 28 from the BD group, 30 from the CTp group, 24 from the CTn group, 17 from the NT group, and 38 from the CTL group. Mean (SD) time from injury to blood collection was similar for all groups with 749.3 minutes (569.5) for BD, 463.6 minutes (569.9) for CTn, 628.6 minutes (523.3) for CTp, and 733.0 minutes (635.4) for NT cohorts. BD subjects had a median S100B concentration of 180 pg/mL (IQR: 77.5-945 pg/mL) compared to 91 pg/mL (IQR: 57.8-281 pg/mL) for CTp, 177.5 pg/mL (IQR: 100.3-321.5 pg/mL) for CTn, 55 pg/mL (IQR: 39-269 pg/mL) for NT, and 63 pg/mL (IQR: 41.8-94 pg/mL) for CTLs (Figure 1). Mean concentrations of S100B were significantly higher in BD subjects than controls ($p < 0.001$; t-test), but no significant differences were present between the BD subjects and any of the comparison groups. Of the BD subjects, median (IQR) concentration of S100B was 210 pg/mL (102.3-612.25 pg/mL) for FD, 55 pg/mL (52-563 pg/mL) for CA/RA, and 1,030 pg/mL (134-1,060 pg/mL) for DAI.

GFAP and UCH-L1 log concentrations were combined and evaluated as predictors of brain death using machine learning with Support Vector Machine (SVM). Log-transformed concentrations of GFAP and UCH-L1 for each sample within the four subject groups and controls were plotted and shown in Figure 2 with contour lines. The area under the curve (AUC) for the brain death cohort was 0.95 (Gaussian kernel, average precision of 0.87) compared to all others (CTL, NT, CTn, CTp); 0.94 [Gaussian kernel, average precision of 0.87]) compared to all brain injury groups (NT, CTn, CTp); and 0.91 [Gaussian kernel, average precision of 0.88]) compared to NT and CTp (Table 4). When the BD group is delineated by mechanism of injury, as plotted in Figure 2, combinations of GFAP and UCH-L1 can predict brain death via CA/RA compared to brain death by FD or DAI with an AUC of 0.96 (Gaussian kernel, average precision of 0.96, Table 4).

The ability of the combination of all 3 biomarkers to predict brain death was also assessed. Log-transformed concentrations of UCH-L1, GFAP, and S100B for each sample within the four subject groups and controls are shown in Figure 2. The AUC for UCH-L1, GFAP, and S100B combination in brain death was 0.98 (Gaussian kernel, average precision of 0.92) compared to all others (CTL, NT, CTn, CTp); 0.96 (Gaussian kernel, average precision of 0.92) compared to all brain injury groups (NT, CTn, CTp); and 0.96 (Gaussian kernel, average precision of 0.95) when compared to NT and CTp (Table 4). The three biomarker combination was also able to distinguish CA/RA brain death from combined NT and DAI brain death with an AUC of 0.99 (Gaussian kernel, average precision of 0.99, Table 4, Figure 2).

DISCUSSION:

The aim of this study was to determine whether or not brain death could be predicted by serum levels of GFAP, UCH-L1 and S100B following traumatic and atraumatic head injury. Our

current ability to prognosticate neurologic outcome following cardiac arrest is poor[22] and, similarly, accurate prognostication following TBI is difficult.[19] Serum biomarkers have been investigated as a means to diagnose, risk-stratify and predict unfavorable outcome in both traumatic and non-traumatic brain injury patients, but few studies have used clinically-confirmed brain death as the main outcome measure.[11, 13, 22-25] In the present study, biomarker concentrations within the first 32 hours post injury were evaluated for their ability to distinguish patients who eventually suffered brain death from those who survived. It is often during this acute post-injury window that families and surrogate decision makers must make critical decisions about whether or not to pursue invasive, life prolonging and costly interventions, yet it is difficult for clinicians to provide realistic expectations as prognostic accuracy is lowest during this time.[22, 26] Biomarkers may identify patients for whom continuation of intensive life-sustaining efforts may prove futile, or conversely, identify patients for whom early induction of intensive therapy may provide maximal utility and offer improved outcomes.[27, 28]

The findings of this study indicate that serum concentrations of GFAP and UCH-L1 are different in subjects who died of brain death as a result of traumatic or atraumatic brain injury when compared to those who survived their TBI with positive head CT, TBI with negative head CT, non-traumatic brain injury, and controls (Figure 1). These findings are consistent with numerous studies that have found a strong association between GFAP and UCH-L1 levels in the acute post-TBI setting and unfavorable outcome including death as measured by the Glasgow Outcome Scale (GOS) or extended GOS (GOSE) at 6 months post-injury[29-33], as well as survival vs non-survival.[34, 35] Moreover, GFAP elevations have previously been shown to predict neurologic outcome following cardiac arrest.[36, 37] This study is among the first to demonstrate the utility of GFAP and UCH-L1 in predicting clinical brain death as opposed to simply mortality.

Combinations of two biomarkers (GFAP and UCH-L1) and three biomarkers (GFAP, UCH-L1 and S100B) were highly predictive of brain death with AUCs greater than 0.90 when compared to all others (CTL, NT, CTn, CTp; AUC = 0.95 and 0.96, AP = 0.87 and 0.92, respectively), brain injury groups (NT, CTn, CTp; AUC = 0.94 and 0.96, AP = 0.87 and 0.92, respectively), and NT and CTp (AUC = 0.91 and 0.95, AP = 0.88 and 0.93, respectively) (Table 4). These AUC values were supported by high average precision (AP) for all comparisons. The inclusion of S100B to the model increased the AUC slightly over the two biomarker combination, indicating that S100B adds predictive value, despite the lack of significant difference in mean concentration compared to individual brain injury groups. As expected, the AUC is highest when compared to all others, which includes both brain injury groups and healthy controls. The AUC remains high even when comparing brain death only to NT and CTp, which is the most clinically relevant distinction.

Among our 19 brain death subjects, two suffered a high velocity TBI consistent with DAI, seven suffered CA/RA and the remaining 10 were found down with unclear or mixed etiology brain injuries. Interestingly, our models with two and three biomarker combinations can distinguish

between patients who suffered brain death via CA/RA as compared to a combined cohort of brain death from NT and DAI with an AUC of 0.96 and 0.99, respectively (Figure 2, Table 4). Of note, this AUC is higher than when comparing BD as a whole to all others (CTL, NT, CTn, CTp; 3 biomarker AUC = 0.96). As observed in Figure 2, CTp follows a similar trend to the DAI BD and FD BD subjects, while the NT group is more closely aligned with the FD BD group, though we could not attempt to statistically verify this association. Our model represents a novel method to differentiate presumed DAI and FD patients from those who suffered CA/RA, which is of particular importance in situations when the underlying neural insult is unknown or ambiguous. We hypothesize that the observed differences are a result of the dichotomous pathophysiology between traumatic and anoxic brain injuries. By comparing mechanism of injury within the brain death group, we avoid some of the variability in severity that was observed within the brain injury (CTp, CTn, and NT) cohorts.

We conclude that serum levels of GFAP, UCH-L1 and S100B drawn within 32 hours post traumatic or non-traumatic brain injury can accurately identify patients who are at significant risk of developing brain death. Importantly, our model can distinguish those who suffered brain death from those who suffered a survived TBI with positive head CT or non-traumatic brain injury, highlighting the potential utility of our model to inform a challenging prognosis. Furthermore, these levels can also categorize brain death subjects by mechanism of injury into either CA/RA or FD and DAI. Classifying the nature of injury represents a first step toward development of therapeutics to reverse the sequelae of injury.

DISCLOSURES Dr. Uzma Samadani reports receiving lecture fees from Abbott; the American Association of Neuroscience Nurses; Cottage Health; Google Inc.; Integra Corp; Medtronic Corp; National Neurotrauma Society; Minnesota, Texas, Louisiana, and Wisconsin Coaches Associations; and the National Football League and USA Football. She also reports receiving grant support from the State of Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program administered by the Minnesota Office of Higher Education, Veterans Administration, Abbott Laboratories, Medtronic, and Integra. Finally, she reports serving as an unaffiliated neurotrauma consultant to the National Football League for five games during each of the 2015–2018 football seasons.

FUNDING

This study was funded by Abbott Labs and the Minnesota State Office of Higher Education Project Number 176016. Neither played a role in generation of the manuscript.

DATA AVAILABILITY

Data will be made available upon reasonable request.

ACKNOWLEDGMENTS

We would like to thank the patients and controls who participated in the study.

REFERENCES:

1.   Truog RD, Krishnamurthy K, Tasker RC. Brain Death-Moving Beyond Consistency in the Diagnostic Criteria. *JAMA*. Sep 15 2020;324(11):1045-1047. doi:10.1001/jama.2020.11665
2.   Vrselja Z, Daniele SG, Silbereis J, et al. Restoration of brain circulation and cellular functions hours post-mortem. *Nature*. Apr 2019;568(7752):336-343. doi:10.1038/s41586-019-1099-1
3.   Murphy L, Wolfer H, Hendrickson RG. Toxicologic Confounders of Brain Death Determination: A Narrative Review. *Neurocrit Care*. Sep 30 2020;doi:10.1007/s12028-020-01114-y
4.   Skarda D, Barnhart D, Scaife E, Molitor M, Meyers R, Rollins M. Extracorporeal cardiopulmonary resuscitation (EC-CPR) for hypothermic arrest in children: is meaningful survival a reasonable expectation? *J Pediatr Surg*. Dec 2012;47(12):2239-43. doi:10.1016/j.jpedsurg.2012.09.014
5.   Pennel T, Beyersdorf F, Gates E, Zilla P. Neurologic recovery after ten minutes of absent cerebral blood flow at normothermia. *Perfusion*. Aug 20 2020:267659120951091. doi:10.1177/0267659120951091
6.   Nguyen D. Brain death and true patient care. *Linacre Q*. Aug 2016;83(3):258-282. doi:10.1080/00243639.2016.1188472
7.   Walker WC, Stromberg KA, Marwitz JH, et al. Predicting Long-Term Global Outcome after Traumatic Brain Injury: Development of a Practical Prognostic Tool Using the Traumatic Brain Injury Model Systems National Database. *J Neurotrauma*. Jul 15 2018;35(14):1587-1595. doi:10.1089/neu.2017.5359
8.   Mesfin FB, Gupta N, Hays Shapshak A, Taylor RS. Diffuse Axonal Injury. *StatPearls*. 2020.
9.   Weinberger LM. Temporary arrest of the circulation to the central nervous system: pathologic effects. *Archives of Neurology And Psychiatry*. 1940;43
10.   Nguyen TV, Hayes M, Zbesko JC, et al. Alzheimer's associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia. *Acta Neuropathol Commun*. Sep 24 2018;6(1):100. doi:10.1186/s40478-018-0603-4
11.   Wang KK, Yang Z, Zhu T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. *Expert Rev Mol Diagn*. Feb 2018;18(2):165-180. doi:10.1080/14737159.2018.1428089
12.   Mahan MY, Thorpe M, Ahmadi A, et al. Glial Fibrillary Acidic Protein (GFAP) Outperforms S100 Calcium-Binding Protein B (S100B) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) as Predictor for Positive Computed Tomography of the Head in Trauma Subjects. *World Neurosurg*. Aug 2019;128:e434-e444. doi:10.1016/j.wneu.2019.04.170
13.   Lorente L. Biomarkers Associated with the Outcome of Traumatic Brain Injury Patients. *Brain Sci*. Oct 27 2017;7(11)doi:10.3390/brainsci7110142
14.   Mondello S, Jeromin A, Buki A, et al. Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. *J Neurotrauma*. Apr 10 2012;29(6):1096-104. doi:10.1089/neu.2011.2092

15.   Kawata K, Liu CY, Merkel SF, Ramirez SH, Tierney RT, Langford D. Blood biomarkers for brain injury: What are we measuring? *Neurosci Biobehav Rev*. Sep 2016;68:460-473. doi:10.1016/j.neubiorev.2016.05.009

16.   Panickar KS, Norenberg MD. Astrocytes in cerebral ischemic injury: morphological and general considerations. *Glia*. Jun 2005;50(4):287-98. doi:10.1002/glia.20181

17.   Papa L, Brophy GM, Welch RD, et al. Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury. *JAMA Neurol*. May 1 2016;73(5):551-60. doi:10.1001/jamaneurol.2016.0039

18.   Diaz-Arrastia R, Wang KK, Papa L, et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. *J Neurotrauma*. Jan 1 2014;31(1):19-25. doi:10.1089/neu.2013.3040

19.   Rodriguez-Rodriguez A, Egea-Guerrero JJ, Gordillo-Escobar E, et al. S100B and Neuron-Specific Enolase as mortality predictors in patients with severe traumatic brain injury. *Neurol Res*. Feb 2016;38(2):130-7. doi:10.1080/01616412.2016.1144410

20.   Mussack T, Biberthaler P, Kanz KG, et al. Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. *Crit Care Med*. Dec 2002;30(12):2669-74. doi:10.1097/00003246-200212000-00010

21.   Cortes C VV. Support-vector networks. *Machine learning*. 1995;Sep 1;20(3):273-97

22.   Geocadin RG, Callaway CW, Fink EL, et al. Standards for Studies of Neurological Prognostication in Comatose Survivors of Cardiac Arrest: A Scientific Statement From the American Heart Association. *Circulation*. Aug 27 2019;140(9):e517-e542. doi:10.1161/CIR.0000000000000702

23.   Egea-Guerrero JJ, Murillo-Cabezas F, Gordillo-Escobar E, et al. S100B protein may detect brain death development after severe traumatic brain injury. *J Neurotrauma*. Oct 15 2013;30(20):1762-9. doi:10.1089/neu.2012.2606

24.   Stefani MA, Modkovski R, Hansel G, et al. Elevated glutamate and lactate predict brain death after severe head trauma. *Ann Clin Transl Neurol*. Jun 2017;4(6):392-402. doi:10.1002/acn3.416

25.   Dimopoulou I, Korfias S, Dafni U, et al. Protein S-100b serum levels in trauma-induced brain death. *Neurology*. Mar 25 2003;60(6):947-51. doi:10.1212/01.wnl.0000049931.77887.7f

26.   Marehbian J, Muehlschlegel S, Edlow BL, Hinson HE, Hwang DY. Medical Management of the Severe Traumatic Brain Injury Patient. *Neurocrit Care*. Dec 2017;27(3):430-446. doi:10.1007/s12028-017-0408-5

27.   Steiner E, Murg-Argeny M, Steltzer H. The severe traumatic brain injury in Austria: early rehabilitative treatment and outcome. *J Trauma Manag Outcomes*. 2016;10:5. doi:10.1186/s13032-016-0035-8

28.   Okonkwo DO, Puffer RC, Puccio AM, et al. Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. *J Neurotrauma*. Dec 1 2020;37(23):2460-2467. doi:10.1089/neu.2020.7140

29.   Okonkwo DO, Yue JK, Puccio AM, et al. GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study. *J Neurotrauma*. Sep 1 2013;30(17):1490-7. doi:10.1089/neu.2013.2883

30.   Bogoslovsky T, Wilson D, Chen Y, et al. Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid beta up to 90 Days after Traumatic Brain Injury. *J Neurotrauma*. Jan 1 2017;34(1):66-73. doi:10.1089/neu.2015.4333

31.   Mondello S, Kobeissy F, Vestri A, Hayes RL, Kochanek PM, Berger RP. Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury. *Sci Rep*. Jun 20 2016;6:28203. doi:10.1038/srep28203

32.   Lei J, Gao G, Feng J, et al. Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study. *Crit Care*. Oct 12 2015;19:362. doi:10.1186/s13054-015-1081-8

33.   Di Battista AP, Buonora JE, Rhind SG, et al. Blood Biomarkers in Moderate-To-Severe Traumatic Brain Injury: Potential Utility of a Multi-Marker Approach in Characterizing Outcome. *Front Neurol*. 2015;6:110. doi:10.3389/fneur.2015.00110

34.   Mondello S, Linnet A, Buki A, et al. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. *Neurosurgery*. Mar 2012;70(3):666-75. doi:10.1227/NEU.0b013e318236a809

35.   Brophy GM, Mondello S, Papa L, et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. *J Neurotrauma*. Jun 2011;28(6):861-70. doi:10.1089/neu.2010.1564

36.   Helwig K, Seeger F, Holschermann H, et al. Elevated Serum Glial Fibrillary Acidic Protein (GFAP) is Associated with Poor Functional Outcome After Cardiopulmonary Resuscitation. *Neurocrit Care*. Aug 2017;27(1):68-74. doi:10.1007/s12028-016-0371-6

37.   Larsson IM, Wallin E, Kristofferzon ML, Niessner M, Zetterberg H, Rubertsson S. Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome. *Resuscitation*. Dec 2014;85(12):1654-61. doi:10.1016/j.resuscitation.2014.09.007

FIGURE LEGENDS:

Figure 1: Boxplots of Log Concentrations of GFAP, UCH-L1 and S100B for Subject Groups and Controls. Concentrations of biomarkers are in picograms per milliliter (pg/mL). Values were log-transformed prior to plotting. Gray represents controls, red represents non-trauma, green represents CT-negative TBI, yellow represents CT-positive TBI, and blue represents brain death.

[A] GFAP

[B] UCH-L1

[C] S100B

Figure 2: Contour and 3D scatterplots of Log Concentrations (pg/mL) of GFAP, UCH-L1, and S100b for comparison groups.

[A] Contour scatterplot of log UCH-L1 and GFAP concentrations for brain death (BD) subjects, brain injury (BI) subjects which includes CT positive TBI, CT negative TBI, and non-trauma, and control (CTL) subjects.

[B] 3D scatterplot of log S100b, UCH-L1, and GFAP concentrations for BD, BI, and CTL subjects.

[C] Contour scatterplot of log UCH-L1 and GFAP concentrations for brain death (BD) subjects, non-trauma (BI) subjects which includes spontaneous intraparenchymal hemorrhages and hypoxic injury, and CT positive TBI (CTp) subjects.

[D] 3D scatterplot of log S100b, UCH-L1, and GFAP concentrations for BD, NT, and CTp subjects.

[E] Contour scatterplot of log UCH-L1 and GFAP concentrations for brain death cohorts: cardiopulmonary arrest (CA/RA), diffuse axonal injury (DAI), and found down (FD) subjects.

[F] 3D scatterplot of log S100b, UCH-L1, and GFAP concentrations for CA/RA, DAI, and FD subjects.

Table 1 - Study demographics cohorts

Data Point		Brain Death	CT (+) TBI	CT (-) TBI	Non-Trauma	Controls
N		19	21	30	15	41
Male \ Female		13 : 6	15 : 6	21 : 9	8 : 7	11 : 30
		P-value (chi squared)	0.84	0.004	0.029	0.00000000001
Age (mean, range)		58.6, 24 - 87	56.2, 31 - 85	50.4, 4 - 95	53.8, 18 - 86	37.1, 16 - 65
		P-value	0.69	0.23	0.42	0.000004
LOC	None	1 (5%)	3 (14%)	15 (50%)	5 (33%)	41
	0 - 30 mins	2 (11%)	6 (29%)	8 (27%)	1 (7%)	-
	30 mins - 24 hrs	0 (0%)	2 (10%)	0 (0%)	1 (7%)	-
	> 24 hrs	14 (74%)	0 (0%)	0 (0%)	0 (0%)	-
	Unknown	2 (11%)	10 (48%)	7 (23%)	8 (53%)	-
GCS	13 - 15	1 (5%)	13 (62%)	28 (93%)	6 (40%)	41
	9 -12	0 (0%)	3 (14%)	1 (3%)	1 (7%)	-
	8 or less	18 (95%)	5 (24%)	1 (3%)	8 (53%)	-
Percent with clinical CT		95%	100%	100%	100%	0 %
Marshall Score (mean, range)		3.1, 1 - 6	2.14, 2 - 4	1	2.47, 1 - 6	-

Length of Stay	0 - 48 hrs	5	7	27	0	-
	49 - 96 hrs	4	5	2	3	-
	> 96 hrs	10	9	1	12	-
Discharge Location	Home	0	13	29	4	-
	Rehab	0	8	1	11	-
	Morgue	19	0	0	0	-

Table 2: Case series serum marker concentrations

Subject	Mechanism of Injury	Age, Sex	GCS	Marshall Score	GFAP			UCH-L1			S100B		
					0 hours (admission)	1 - 8 hours post injury	12 - 32 hours post injury	0 hours (admission)	1 - 8 hours post injury	12 - 32 hours post injury	0 hours (admission)	1 - 8 hours post injury	12 - 32 hours post injury
CA/RA-1	Cardiac arrest	Middle age, M	3T	n/a	15.4	27.0	946.7	4,163.6	4,486.1	2,844.6	1,030.0	52.0	41.0
CA/RA-2	Cardiac arrest	Older, M	3T	1	17.4	30.8	-	4,566.7	11,416.8	-	-	-	-
CA/RA-3	Cardiac arrest	Younger, F	3T	3	37.7	78.5	-	1,067.7	561.7	-	55.0	53.0	-
CA/RA-4	Cardiac arrest	Middle age,M	3T	1	53.0	32.2	474.1	13,620.1	12,845.9	9,783.6	-	-	-
CA/RA-5	Fall off bike vs cardiac arrest	Older, M	3T	2	NA	220.6	9,990.2	-	0.4	258.2	563.0	83.0	50.0
CA/RA-6	Overdose	Middle age, M	3T	3	34.7	80.9	-	4,357.6	2,615.2	-	1,180.0	-	-
CA/RA-7	Found down - SDH and cardiac arrest	Older, F	3T	6	471.3	46,611.1	-	>20,000	>20,000	-	-	-	-
FD-1	Found down - spont IPH	Middle age, M	5T	4	2,301.2	-	-	437.6	-	-	-	-	-
FD-2	Found down - spont IPH	Older, F	3	6	22,434.9	>50,000	41,925.7	976.7	649.8	775.6	2,180.0	583.0	237.0
FD-3	Found down - spont IPH	Middle age, M	3	4	42,863.3	24,959.7	26,684.4	1,866.0	386.3	303.6	920.0	622.0	327.0

FD-4	Found down - spont IPH	Older, F	4	4	>50,000	-	-	986.5	-	-	1,020.0	-	-
FD-5	Found down - spont IPH	Middle age, F	3	3	>50,000	-	-	650.7	-	-	177.0	-	-
FD-6	Found down - spont IPH	Middle age, M	3	2	18,202.3	-	21,738.1	2,280.1	-	464.9	-	-	-
FD-7	Spontaneous IPH	Middle age, M	3	2	2,934.1	-	-	38.1	-	-	183.0	-	-
FD-8	Spontaneous IPH	Middle age, M	13	2	-	5,692.9	3,177.7	-	183.0	175.7	-	-	-
FD-9	Found down	Older, M	5	4	13,671.4	17,459.0	38,300.4	9,113.7	2,863.4	2,225.8	5.0	109.0	90.0
FD-10	Unwitnessed fall	Older, F	3	3	32,136.0	-	>50,000	10,585.1	-	1,939.2	100.0	-	61.0
DAI-1	MVC roll over polytrauma	Younger, M	3T	2	48,064.2	11,961.1	33,018.7	2,830.4	435.8	1,245.8	1,060.0	1,400.0	1,030.0
DAI-2	MVC	Older, M	3	3	13,284.3	-	>50,000	7,050.0	-	3,304.1	134.0	-	112.0

Table 3: Characterization of brain death biomarkers

Biomarker		Brain Death	CT (+) TBI	CT (-) TBI	Non-Trauma	Controls
GFAP	samples (n)	40	46	49	27	41
	mean, stdev	18,248.3, 19,254.6	2,871.7, -4,992.5	134.8, 263.7	2,489.5, 6,104.3	13.5, 14.4
	range	15.4 - 50,000	33.2 - 22,178.8	4.7, 1,426.1	3.3 - 27,985	0.6 - 84.5
	t test p value vs brain death	-	0.0000133	0.0000006	0.0000135	0.0000005
UHC-L1	samples (n)	40	46	49	27	41
	mean, stdev	4,108.9, 5,287.1	637.9, 685.8	381.2, 639.6	433.0, 718.2	90.6, 70.9
	range	0.4 - 20,000	4.2 - 2918.5	56 - 4,347.2	45.4 - 3,125.3	0 - 370.5
	t test p value vs brain death	-	0.0001830	0.0000709	0.0000910	0.0000230
S100B	samples (n)	28	30	24	17	38
	mean, stdev	480.6 - 548.6	403.6, 883.0	551.5, 1,316.6	275.2, 468.4	74.3, 42.1
	range	5 - 2,180	16 - 4,280	25 - 6450	23 - 1,840	17 -207
	t test p value vs brain death	-	0.6940469	0.8071675	0.2060105	0.0005538

Table 4: Support vector machine comparison of diagnostic prediction accuracy

Comparison Groups	Kernel Function	GFAP and UCH-L1		GFAP, UCH-L1, and S100b	
		AUC	*AP*	*AUC*	*AP*
Brain Death vs CTL, NT, CTn, CTp	Gaussian Kernel	0.954	0.868	0.975	0.922
	Polynomial kernel	0.955	0.872	0.982	0.945
Brain Death vs NT, CTn, CTp	Gaussian Kernel	0.940	0.869	0.964	0.923
	Polynomial kernel	0.941	0.872	0.974	0.946
Brain Death vs NT, CTp	Gaussian Kernel	0.912	0.875	0.947	0.930
	Polynomial kernel	0.921	0.885	0.960	0.946
Cardiopulmonary Arrest vs FD and DAI	Gaussian Kernel	0.964	0.961	0.989	0.980
	Polynomial kernel	0.948	0.951	0.978	0.958